High MET expression is an adverse prognostic factor in patients with triple-negative breast cancerFlora Zagouri, Martin Filipits, Zsuzsanna Bagó-Horváth et al.|British Journal of Cancer|2013Cited by 98
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).W Janni, Bogusława Karaszewska, W. Wiest et al.|Journal of Clinical Oncology|2010Cited by 2